B19 parvovirus has been shown to persist in some immunocompromised patients, and treatment with specific antibodies can lead to decreased quantities of circulating virus and hematologic improvement. A defective immune response to B19 parvovirus in these patients was shown by comparison of results using a capture RIA and immunoblotting. In normal individuals, examination of paired sera showed that the dominant humoral immune response during early convalescence was to the virus major capsid protein (58 kD) and during late convalescence to the minor capsid species (83 kD). In patients with persistent parvovirus infection, variable titers against intact particles were detected by RIA, but the sera from these patients had minimal or no IgG to capsid proteins determined by Western analysis. Competition experiments suggested that this discrepancy was not explicable on the basis of immune complex formation alone and that these patients may have a qualitative abnormality in antibody binding to virus. In neutralization experiments, in which erythroid colony formation in vitro was used as an assay of parvovirus activity, sera from patients with poor reactivity on immunoblotting were also inadequate in inhibiting viral infectivity. A cellular response to purified B19 parvovirus could not be demonstrated using proliferation assays and PBMC from individuals with serologic evidence of exposure to virus. These results suggest that production of neutralizing antibody to capsid protein plays […] Abstract B19 parvovirus has been shown to persist in some immunocompromised patients, and treatment with specific antibodies can lead to decreased quantities of circulating virus and hematologic improvement. A defective immune response to B19 parvovirus in these patients was shown by comparison of results using a capture RIA and immunoblotting. In normal individuals, examination of paired sera showed that the dominant humoral immune response during early convalescence was to the virus major capsid protein (58 kD) and during late convalescence to the minor capsid species (83 kD). In patients with persistent parvovirus infection, variable titers against intact particles were detected by RIA, but the sera from these patients had minimal or no IgG to capsid proteins determined by Western analysis. Competition experiments suggested that this discrepancy was not explicable on the basis of immune complex formation alone and that these patients may have a qualitative abnormality in antibody binding to virus. In neutralization experiments, in which erythroid colony formation in vitro was used as an assay of parvovirus activity, sera from patients with poor reactivity on immunoblotting were also inadequate in inhibiting viral infectivity. A cellular response to purified B19 parvovirus could not be demonstrated using proliferation assays and PBMC from individuals with serologic evidence of exposure to virus. These results suggest that production of neutralizing antibody to capsid protein plays a major role in limiting parvovirus infection in man.
Introduction
B19 parvovirus infection in man is usually acute (1, 2). The only identified target cell for this virus is an erythroid progenitor of the bone marrow (3, 4) . Infection in normal individuals is manifest as fifth disease, in which the formation of complexes of antibody and virus is associated with a cutaneous eruption and polyarthralgia (5) . In normal persons, infection leads to reticulocytopenia with viremia shortly after inocula-tion, but the decline in hemoglobin is minimal because of the brief interruption of erythropoiesis (5) . In contrast, in individuals with an increased requirement for erythrocytes and heightened marrow erythopoiesis (hemolysis, ineffective erythropoiesis, blood loss, iron deficiency), B19 parvovirus causes transient aplastic crisis, in which the dominant clinical feature is abrupt worsening of anemia (2). In these infected individuals, the period of viremia is short, and the appearance of virus-specific antibody is followed by brisk marrow recovery.
We have identified patients with persistent B 19 parvoviremia that has resulted in chronic bone marrow failure. The first reported case was a patient with Nezelof's syndrome (combined immunodeficiency with immunoglobulins); virus was detected in this child's blood for > 18 mo and hemoglobin and neutrophil number were inversely related to viral titer (6) . Another patient with a similarly limited clinical immunologic deficit has been studied by us, in whom parvovirus has been persistent for at least 3 and possibly > 10 yr, also resulting in chronic severe anemia (7) . Persistent B19 parvovirus infection also may be particularly common among children receiving immunosuppressive chemotherapy for cancer, as the peak incidence of B 19 parvovirus infection is in children. Several children with acute lymphocytic leukemia in remission and on maintenance chemotherapy have had chronic anemia and repeatedly viremic sera (8) . Finally, we have detected virus in the sera of patients with AIDS who presented with the clinical syndrome of pure red cell aplasia (Frickhofen, N., G. Kurtzman, and N. S. Young, unpublished data).
The host immune response to viruses is complex, and some viruses predominantly elicit either a cellular or humoral immune response (9) . Even when neutralizing antibodies or a specific cellular response can be demonstrated in vitro, the protective role of the humoral or cellular arms of the immune system is often inferred from clinical studies ofsusceptibility in immunosuppressed patients or the results of vaccination. The effectiveness of passive immunization with immunoglobulin (hepatitis A, cytomegalovirus) or hyperimmune serum (hepatitis B, varicella) implies a primary role of antibody in protection against some virus infections. To begin to elucidate the immune response to B 19 parvovirus infection, we have studied the antibody and cellular responses to infection in acute and chronic disease.
Methods
Patients. Blood from six patients with persistent B 19 parvoviremia was studied (Table I) . The first case, T.W. (6) at presentation was a 31/2-yrold boy with combined immunodeficiency with immunoglobulins (Nezelof's syndrome). He became abruptly anemic and granulocytopenic at age 1l/2yr, when his serum for the first time contained virus; he has been intermittently viremic and transfusion-dependent for more (14) . Electron microscopy was performed on pellets after ultracentrifugation of 50 ,l of serum; negative staining was done using 3% phosphotungstic acid, pH 6.5. Immunoblot. Virus from the serum of a patient with transient aplastic crisis was separated from other serum components by centrifugation through 40% sucrose at -100,000 g for 6-16 h (4). Virus was resuspended in PBS and, after heating to 90-100°C for 10 min under reducing conditions, electrophoresed in 8% SDS-polyacrylamide (15) . After electrophoretic transfer to nitrocellulose, individual lanes were incubated with separate sera in a Deca-Probe apparatus (Hoefer Scientific Instruments, San Francisco, CA) for 1 h at room temperature. IgG was detected by incubation ofthe filter with '251-Protein A or '251I-goat anti-human IgG (New England Nuclear, Boston, MA) and IgM by incubation with rabbit anti-human IgM (Miles Laboratories, Naperville, IL) followed by '251-goat anti-rabbit IgG (New England Nuclear) by the nonfat dry milk-antifoam-thimerosal (16) method.
Detection of neutralizing antibody. Sera from the patient were tested for their ability to abrogate the cytotoxic effect of B19 virus in erythroid colony formation assays (3, 4 6 . Test mitogens and antigens included PHA, Con A, PWM, candida, tetanus toxoid, streptolysin 0, and dilutions of partially purified B 19 parvovirus or empty parvovirus capsids. Virus was purified by passage of serum over a 40% sucrose cushion at 38,500 rpm X 16 h and suspension of the pellet in -100 MAl of PBS; samples from uninfected sera were prepared similarly. Virus content was estimated by dot-blot analysis with a radioactively labeled virusspecific DNA probe. The serum used (Gray) contained only virus and was free of immune complexes as determined by electron microscopy. In addition, a lysate of a genetically engineered cell line that produces empty B 19 parvovirus capsids (17) . . x ; . . S . ra _<.
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. (19) or by rabbit polyclonal serum directed against fusion proteins, which were produced in genetically altered bacteria that carry a portion ofthe capsid protein gene (20) . We examined 15 sera from patients in whom B 19 parvovirus infection had been established by detection of antibodies in a capture radioimmunoassay; on Western analysis, antibody specificities for either the 58-kD capsid protein, the 83-kD capsid protein, or both species were always present. Examination of paired specimens from early and late during the convalescent phase showed a consistent pattern of protein recognition (Fig. 1 A) . At the time of viremia, IgG antibody to virus was often not detected by immunoblot; however, when it was detected, sera reacted only with the major capsid protein of 58 kD. During early convalescence (< 1 wk from viremia), antibody to the major capsid protein was the predominant or exclusive reactivity. Weeks to months after infection or in sera from an immune population routinely screened, reactivity to the 83-kD protein was present and often dominant. Because much less ofthe 83-kD protein is present in virus and therefore on the nitrocellulose used for immunoblotting, the Western method probably underestimated the amount of 83-kD specific antibody in serum. In addition, failure to detect a major capsid protein reaction indicated that epitopes present at the amino-terminal end of the 83 kD, which are not shared between the two capsid proteins, are specifically recognized. There was no reaction of immune sera to a mock preparation of antigen from a nonviremic individual (Fig. 1 B) , nor did nonimmune sera from normal individuals or frequently transfused patients with hematologic diseases bind to parvovirus capsid proteins (Fig. 1 C) .
Commercial immunoglobulin preparations also contained anti-B 19 parvovirus antibodies. All of seven lots (six Gammimune, Cutter, Elkhart, IN; one Gammagard, Hyland, Glendale, CA) contained antibodies determined by RIA, and four of four lots showed specificities to both 58-and 83-kD capsid proteins by immunoblot (Fig. 2) .
Antibody response to B19 parvovirus in persistent infection.
In the first case of persistent infection, both IgM and IgG antibodies specific for B19 parvovirus were readily detected by (Fig. 3) . However, multiple serum samples failed to react with electrophoresed capsid proteins on immunoblotting for Bl 9 parvovirus-specific IgG and IgM (Fig. 4) . (Apparent slight reactivity in one sample only was probably due to recent transfusion with immune plasma from the patient's father.)
To determine whether the absence of anticapsid protein specificity in serum on immunoblot was a consistent feature of persistent infection, we examined sera from other patients -97 4 with chronic B 19 parvoviremia (Fig. 5) . Persistent parvovirus -68 infection has been documented in children with acute lymphocytic leukemia in remission receiving immunosuppressive chemotherapy. Sera obtained from these children during periods --43 of viremia and anemia failed to react with capsid proteins on immunoblotting and also had low titers of virus-specific IgG -2 5. 7 and IgM on RIA, whereas sera from periods in which virus temporarily disappeared from the circulation and at ultimate recovery did react on immunoblot (Table I) . In a patient with l-)( AIDS who clinically presented with pure red cell aplasia, antibody initially was lacking by both tests. He later recovered erythropoiesis with immunoglobulin therapy (10) . A serum 46 sample obtained 1 yr later showed high antibody titers by RIA but no reactivity on Western analysis. As summarized in Table  I , no reaction or, in one case (E.Fo.), a weak reaction on immunoblotting was a consistent feature ofthe immune response in patients who developed virus persistence. Reactivity of sera from patient E.Fo., as well as from the two patients with leukemia after eventual clearance of virus, was only directed against the 58-kD major capsid protein, and these sera consistently failed to detect the 83-kD minor capsid protein.
Discordance between the results of the capture RIA, immune electron microscopy, and immunoblot might have a quantitative or qualitative explanation. As the RIA and electron microscopy also detect immune complexes (14) , a quantitative defect in antibody production could result in a defi- We tested sera for their ability to abrogate inhibition of erythroid colony formation by virus, comparing sera from two patients that contained anti-B19 parvovirus antibodies (Fig.  6) . Compared with sera from normal persons, who were selected for similar titers of anti-B19 parvovirus IgG or IgM determined by capture RIA, the serum of the child with Nezelof's syndrome was obviously deficient in neutralizing activity (Fig. 6 A) . Similarly, the serum from a patient with acute lymphocytic leukemia in remission also had very poor neutralizing activity in comparison to another normal convalescent phase serum (Fig. 6 B) . Sera from both persistently infected patients had poor reactivity on Western analysis but measurable titers of antibody by capture RIA.
Although sera from normal exposed individuals consistently neutralized virus, there were differences in potency among sera at dilutions higher than 1:50, and the sera that were most effective at blocking virus infectivity also showed the intensest reaction on immunoblot (Fig. 7) . These results suggest that the ability of sera to react with denatured capsid proteins on immunoblot could be approximately correlated to their capacity to neutralize virus infectivity. We similarly compared serum specimens in which reactivity on immunoblot was predominantly directed to the major capsid species (58 kD) or to the minor capsid protein (83 kD) (Fig. 8) . The equivalent neutralizing ability ofthese sera indicated that even serum containing antibody restricted to the unique portion of the minor capsid protein, as develops during convalescence, was fully capable of inhibiting infectivity of virus.
Inability to detect a cellular response to B19 parvovirus. Multiple attempts were made to detect a proliferative response by peripheral blood cells to B19 parvovirus. Using preparations of unfractionated blood mononuclear cells from seropositive normal donors, variable concentrations of purified virus, and different times for harvest ofcultures, no increase in incorporation of radioactive thymidine was observed (Fig. 9) . Because ofthe possibility that immune complexes formed with antibodies present in autologous serum might block cell access or inhibit proliferation, experiments were performed in which FCS or parvovirus antibody-negative human serum replaced autologus serum, and empty parvovirus capsids generated from a cell line and serum containing virus served as antigens. Under these conditions, we were again unable to detect a proliferative response to virus antigen at 3-7 d (data not shown).
Discussion
In normal individuals infected, either naturally or experimentally, with B19 parvovirus antibodies to virus form rapidly, usually within a week of inoculation (21) . Fifth disease is itself an antibody-mediated, probably immune complex disorder, occurring at the time that antibodies are present in the circulation and seldom associated with the presence of virus in serum (22 therapy.) On immunoblot of normal sera early after infection, antibody specificity to the 58-kD capsid protein predominates; a similar result has been recently reported by others (23) . The amino acid sequence of the 58-kD major capsid protein is contained within the 83-kD minor capsid sequence, and antibodies may recognize some unique features of the major capsid protein. Such MAbs with specificity for the major capsid protein of canine parvovirus have been produced (24) . Late in convalescence the 83-kD species antibody specificity predominates; these antibodies presumably recognize the unique 227-amino acid region of the larger protein. The topology of the major and minor proteins on the parvovirus capsid surface is not known. The unique region of the 83-kD protein has areas of pronounced hydrophilicity and several predicted alpha helices at the amino terminus, which might contribute to its immunogenicity (25) . Formation of neutralizing antibodies is a consistent feature ofacute infection in animals by members ofParvoviridae (26) . Diluted sera from patients who have been exposed to the virus Persistent infection of animal parvoviruses in young hosts is common: virus is shed in feces and urine for long periods after initial inoculation, during either convalescence or in latent infection, in mink (34), cats (35) , and pigs (36) . The relationship of persistent animal parvovirus infection to antibody production is complicated. Formation of neutralizing antibodies is believed to have a major role in resolution of acute infection in adult animals (37), but virus-specific antibodies are often present in persistently infected neonatal animals, and abnormally elevated titers of antibody have been associated with latency. Reappearance of clinical illness in animals has followed immunosuppressive therapy. In Aleutian mink disease, which is chronic and often fatal, tissue damage is the result of deposition of immune complexes of parvovirus antigen and antiviral IgG antibodies that fail to neutralize virus (38) .
In our experiments, there was discordance between the results of capture RIA and immunoblot in detection of antiparvovirus antibody. As these patients were viremic, one obvious explanation is that antivirus antibody was present in complex with virus. Such complexes with IgM were visualized by electron microscopy of T.W.'s sera. Antibodies in immune complexes would be predicted to be detected in the capture RIA, as they would bind to plastic coated with anti-human IgG and IgM antibodies, and virus in complexes could be recognized by the antivirus MAb. In the absence of free antibody or antigen binding sites, antivirus antibody in complexes would not be detected in immunoblot. However, control experiments showed that failure to react on immunoblot was not a consequence of immune complex formation. A qualitative antibody defect was further suggested by the presence of some activity in neutralization assays, indicating the availability of free antigen bindings sites. These results suggest that some patients (leukemia in remission with chemotherapy) do not produce anti-B19 parvovirus antibody (a quantitative defect) and that other patients (congenital and acquired immunodeficiency) may produce antibodies that fail both to recognize capsid protein epitopes and to neutralize virus activity. An example of a combined quantitative and qualitative defect in antibody production in response to viruses is infection of ferrets with Aleutian disease virus: in animals with low titers of antibody, antibody is directed primarily against conformational virus determinants, whereas ferrets with high titers also produce antibody to sequential determinants detectable on Figure 9 . Cellular response to parvovirus. Peripheral blood mononuclear cells from patient T.W. with persistent infection, his mother (with high titers of anti-B1 9 antibodies by RIA), three individuals with serologic evidence of past parvovirus infection (S.S., J.H., and G.K.) and a seronegative person (H.L.) were assayed for proliferation in response to purified B1 9 parvovirus at varying concentrations (1 2`-1O-' dilutions of a preparation that contained genome 1O" genome copies/ml; shaded bars), to normal sera processed as for virus purification (open bars), and to test antigens candida, tetanus, and PHA. Cells incubated in medium without antigen or mitogen served as a negative control (medium). In this experiment, cells were incubated for 7 Western analysis (39) . In general, animals repeatedly exposed to antigen not only switch from IgM to IgG production but also show progressively higher levels of IgG with increasing affinity and specificity (40) . The late production in normal persons of neutralizing IgG that is directed toward more restricted epitopes on the Bl9 parvovirus minor capsid species may be the result of selection of B cell clones. In patients persistently infected with B19 parvovirus, the prolonged period of elevated antivirus IgM (Table I) as well as the lack of antibody specificity for the 83-kD minor capsid species would also support a class switching defect.
The major immune response to B 19 parvovirus appears to be humoral. Based on these data, we have treated several persistently infected patients with immunoglobulin preparations. T.W. received both his father's plasma and commercial immunoglobulin; he experienced a transient reticulocytosis to 8% and erythroid precursors appeared in the bone marrow, although the hemoglobin did not rise, possibly due to iatrogenic hemolysis from the high concentrations of IgG infused. E.Fr. underwent a course of treatment with his father's plasma and experienced a brief reticulocyte response as well as severe fifth disease; sufficient plasma could not be administered to sustain antiparvovirus immunoglobulin levels. E.Fo. has received very high doses ofcommercial IgG and has had a complete hematologic remission, associated with disappearance of virus from the circulation (7) . Correction of the antibody deficit in persistently infected patients may allow reversal oftheir hematologic disease.
